美国堪萨斯大学短期毕业实习项目

发布者:孙恬发布时间:2018-09-11浏览次数:666


美国堪萨斯大学(University of Kansas),简称KU,坐落在美国堪萨斯州的劳伦斯市,创建于1862年,具有超过150年的建校史,现已成为美国著名的公立研究型大学之一。堪萨斯大学是美国大学协会(AAU)的成员校之一,该协会由美国及加拿大受到广泛认可的62所名校组成。学校设有16个学院(Academic Schools)、200多项专业课程,约有30,000位学生在此学习,专任教师就有2,100人之多,其中92%拥有该学术领域的最高学历与权威。堪萨斯大学被《美国新闻与世界报道》评为美国前50的公立大学,一直以来被公认为是全美顶级的研究型大学。

堪萨斯大学遴选出数个教授实验室以及颇具实力的指导教师来参与此项目,指导中方选派学生完成毕业实习工作,中国药科大学负责从优选派3名大四全日制在读本科生赴美,时长为一学期。

录取学生可申请国际交流基金资助 http://gjc.cpu.edu.cn/3b/8d/c1367a15245/page.htm

  

招生条件:

1、现为我校相关专业大四全日制在读本科生;

2、具备良好的英语听说能力;

3、必修课程无不及格记录,GPA3.0以上;

4、有一定经济能力;

5、具备相关课题的科研基础;

  

留学时间:次年2月初---次年5月底

  

招生专业:药学院、生科院、中药院所有专业人员以及制药工程专业学生

  

报名需提交材料:

1Personal statement which should include your CV, study in CPU, one to three interested professors in USC and study plan

2Transcripts

3Two recommendation letters

4TOEFL or IELTS scores

(以上材料都需提交英文版本)


  

咨询以及报名方式:

玄武门校区留学生楼国际处薛老师 (外方讯息、奖学金申请、申请材料咨询 xlmcpu@126.com

918日前至江宁校区行政中心205室教务处孙老师报名(现场报名、资格审核 86185202

  

  

部分可选导师相关信息:

Dr. Teruna J. Siahaan

Aya & Takeru Higuchi Distinguished Professor

Department of Pharmaceutical Chemistry, The University of Kansas

https://pharmacy.ku.edu/teruna-siahaan#link2

Professor Siahaan's research interests are in the utilization peptides for targeted drug delivery to a specific cell type and for increasing drug permeation through the intestinal mucosa and blood-brain barrier (BBB). Dr. Siahaan’s group is interested in synthesis, structural studies of cyclic peptide and evaluation of their activities in in vitro and in vivo biological systems. Dr. Siahaan’s group is using E-cadherin peptides to enhance permeation of large hydrophilic molecules (i.e., peptides and proteins) through the intestinal mucosa and BBB. His group is also using peptides derived from cell adhesion molecules (i.e., ICAM-1 and LFA-1) to target drugs to leukocytes and vascular endothelial cells in inflammatory and autoimmune diseases (i.e., rheumatoid arthritis). Cell adhesion peptides are being used to target antigenic peptides (i.e., bi-functional peptide inhibitor (BPI)) to block the formation of the immunological synapse at the interface between T cells and antigen presenting cells (APC). BPI molecules have been shown to suppress autoimmune disease models such as multiple sclerosis, type-1 diabetes and rheumatoid arthritis.

Dr. Thomas Tolbert

Associate Professor

Department of Pharmaceutical Chemistry, The University of Kansas

https://pharmacy.ku.edu/thomas-tolbert

Dr. Tolbert is focused on studying the role of glycosylation in antibody-dependent immune responses and synthesis of glycoconjugates. Dr. Tolbert is also working on fusion proteins of antibody Fc regions fused to bioactive peptides to increase the in vivo half-lives of peptides used to treat diabetes. He started a collaboration with Professor Siahaan to produce peptide-Fc fusion proteins, which will function as bifunctional peptide inhibitor molecules to control PLP- and MOG-stimulated EAE. Dr. Tolbert’s laboratory has protein expression experience and facilities and is well prepared to aid in the generation of large amounts of recombinant proteins.

  

Dr. Zhuo (Michael) Wang

Associate Professor

Department of Pharmaceutical Chemistry, The University of Kansas

https://pharmacy.ku.edu/michael-wang

Dr. Wang is interested in drug metabolism, pharmacokinetics, and pharmaceutical analysis. Dr. Wang has seven-year experience leading a Pharmacology/Bioanalytical team supporting drug discovery and development programs within the Consortium for Parasitic Drug Development (CPDD), a public-private partnership aimed to develop new treatments for human African trypanosomiasis and leishmaniasis. Dr. Wang has established an independent research program focused on analytical and pharmaceutical research that brings novel and improved bioanalytical methodologies to drug analysis and pharmaceutical sciences. He has the expertise, leadership and motivation necessary to successfully carry out the proposed studies.